Relmada Therapeutics Inc (RLMD)’s stock has witnessed a price hike of 25.89% from the previous close with its current price standing at $1.41. Its current price is -64.57% under its 52-week high of $3.98 and 486.52% more than its 52-week low of $0.24. Based on the past 30-day period, the stock price is -3.83% below the high and +127.27% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, RLMD’s SMA-200 is $0.6637.
How does Relmada Therapeutics Inc (RLMD) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 4 brokerage firms that recommend the stock as a Hold. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 3.00 in simple terms.
Relmada Therapeutics Inc (RLMD): Earnings History
If we examine Relmada Therapeutics Inc’s recent earnings history, in the last quarter ended on 3/31/2025, it posted adjusted earnings per share of -$0.58, beating the consensus of -$0.31. In other words, it beat the consensus by -$0.27, resulting in a -87.10% surprise. In the 3 months period before the previous quarter which was closed on 3/31/2025, the stock recorded adjusted earnings per share of -$0.58 in contrast with the Outlook of -$0.31. That was a difference of -$0.27 and a surprise of -87.10%.
Relmada Therapeutics Inc (RLMD): Earnings History
Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 2 different analysts, who are expecting earnings to fall in between the range of -0.04 and -0.19 with an average Earnings Estimate of -0.12 which is in contrast with the last year earnings estimate of -0.72 and also replicates 83.33% growth rate year over year.
Relmada Therapeutics Inc (NASDAQ: RLMD) Ownership Details
I will give a breakdown of the key shareholders in Relmada Therapeutics Inc (RLMD). Recent figures show that the company’s insiders hold 18.85% of shares. A total of 60 institutional investors hold shares in the company, making 34.35% of its stock and 42.33% of its float.
Jul 31, 2025, it was reported that the Company’s largest institutional holder is AdvisorShares Trust-AdvisorShares Psychedelics ETF holding total of 425.6 shares that make 4.30% of the company’s total number of shares and are currently priced at 0.58 million.
The securities firm VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund holds 353.62 shares of RLMD, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 3.57%, and the holding percentage of shares is valued at 0.48 million.
An overview of Relmada Therapeutics Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Relmada Therapeutics Inc (RLMD) traded 1,137,197 shares per day, with a moving average of $0.6782 and price change of +0.6350. With the moving average of $0.6438 and a price change of +0.5715, about 622,243 shares changed hands on average over the past 50 days. Finally, RLMD’s 100-day average volume is 1,387,105 shares, alongside a moving average of $0.5875 and a price change of +0.9982.
